SELF-REPORT CREDIT FORM

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and the National Institutes of Health. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The Johns Hopkins University School of Medicine designates this educational activity for 1 credit per session for a maximum of 44 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Clinical Center Grand Rounds
Lipsett Amphitheater
12 Noon – 1 p.m.
March 23, 2011

PARP Inhibitors: How Successful Have We Been in Modulating DNA Damage?
Elise C. Kohn, M.D., Head, Medical Ovarian Cancer Clinic, and Head, Molecular Signaling Section Medical Oncology Branch, Center for Cancer Research, NCI

The Evolving Role of PARP Inhibitors in Breast and Ovarian Cancers
Shivaani Kummar, M.D., Head, Early Clinical Trials Development, Office of the Director, Division of Cancer Treatment and Diagnosis, NCI

NOTE: To receive credit for attendance, this form must be returned to the Office of Clinical Research Training and Medical Education by 4 pm on the day of the lecture. Please fax forms to 301-435-5275. For CC Grand Rounds CME inquiries, contact Avril Bertrand at 301-496-9424 or bertranda@cc.nih.gov

<table>
<thead>
<tr>
<th>Date(s)</th>
<th>Maximum Approved Hours per session/per week</th>
<th>Earned Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 23, 2011</td>
<td>1 hour per session/per week</td>
<td>1.0*</td>
</tr>
</tbody>
</table>

Please Print Clearly
Please check one: _____Physician _____Non-Physician

__________________________________________________________________________
NAME - LAST FIRST MI

NIH BADGE NUMBER (IF NIH EMPLOYEE)

PHONE EMAIL ORGANIZATION INSTITUTE/CENTER DEPT/BRANCH

ADDRESS CITY STATE ZIP + 4

SIGNATURE REQUIRED for ALL ATTENDEES:
I attest that the above number credit hour(s) is correct.

X ___________________________ Date ___________________________
Signature of Attendee

*These hours will be verified by the Office of Continuing Medical Education (OCME) and recorded on your official Transcript.
EVALUATION FORM
Clinical Center Grand Rounds at the National Institutes of Health
March 23, 2011

Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all  2 - Very little  3 – Moderately  4 – Considerably  5 – Completely  N/A - Not applicable

Speaker: Elise C. Kohn, M.D.

Objective: To understand applications of PARP inhibitors for women with breast and/or ovarian concerns

A. Rating of Objectives and Activity

1. Please rate the attainment of objectives:
   a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
   c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A

2. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

3. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias? Use the following criteria to judge?
   a) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ____No  ____Yes
      If no, please specify: ________________________________
   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ____No  ____Yes
      If no, please specify: ________________________________
   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ____No  ____Yes
      If no, please specify: ________________________________

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?
   _______________________________________________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
   _______________________________________________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
   _______________________________________________________________________________

4. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity? ___Yes  ___No  If yes, please provide your email: _____________________________
EVALUATION FORM
Clinical Center Grand Rounds at the National Institutes of Health
March 23, 2011

Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all  2 - Very little  3 – Moderately  4 – Considerably  5 – Completely  N/A - Not applicable

Speaker: Shivaani Kummar, M.D.

Objective: Discuss the current status of the data from clinical trials utilizing PARP inhibitors

A. Rating of Objectives and Activity

5. Please rate the attainment of objectives:
   a. Define options and alternatives that will guide clinical practice  1  2  3  4  5  N/A
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances  1  2  3  4  5  N/A
   c. Analyze information and opportunities to increase and improve collaboration between investigators  1  2  3  4  5  N/A

6. The overall quality of the instructional process was an asset to the activity:  1  2  3  4  5  N/A

7. To what extent did participation in this activity enhance your professional effectiveness?  1  2  3  4  5  N/A

4. Will you change your practice in any way as a result of attending this activity?  1  2  3  4  5  N/A

5. Did you perceive any commercial bias?
   Use the following criteria to judge?

   b) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ____No  ____Yes
      If no, please specify: _______________________________________________________

   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ____No  ____Yes
      If no, please specify: _______________________________________________________

   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ____No  ____Yes
      If no, please specify: _______________________________________________________

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?
______________________________________________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
______________________________________________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
______________________________________________________________________________

8. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity? ___Yes  ___No  If yes, please provide your email: _________________________________